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ANNEXURE
                                            INTRODUCTION 
Acquired Immuno Deficiency Syndrome (AIDS) is one of the most feared pandemic infections 
of the present world, which brought out hitherto unheard infections into limelight. The World 
Health Organization (WHO) estimated that more than 39 million persons were living with HIV 
infection at the end of 2004, including 2.2 million children [1].
AIDS  is  caused  by  the  Human  immuno  deficiency  virus  (HIV),  which  was  first 
discovered by Robert Gallo in 1981. HIV-1 and HIV-2 are RNA viruses belonging to 
the family of Retroviridia of genus Lentivirus. HIV-1 is divided into three major groups 
namely M, O, and N and further into subtypes.  Group M (Major) is  divided into 9 
subtypes of which subtype `C' is commonly found.
HIV-1 genome contains two copies of single stranded RNA with three major sections 
which are:
GAG region encoding viral core proteins namely p24, p17, p9 and  p6.
- POL  region  encoding  viral  enzymes  namely  reverse  transcriptase   (p51), 
protease (p10) and integrase (p32).
- ENV region encoding viral envelope proteins - gp120 and gp41.
Other genes in the HIV-1 genome are tat, rev, nef, 
vif, vpr and vpu. It does not contain vpx segment 
HIV-1 is  the  common type in  India[3].  Whereas 
HIV-2 is seen predominantly in sub Saharan Africa 
with the the following unique features:
           - lower rate of vertical transmission
           - possible protection against HIV-1 infection
           - lower levels of plasma TNF alfa
           - lower viral load
           - lower level of proviral DNA in circulating lymphocytes
           - Non Nucleoside Reverse Transcriptase Inhibitor resistant
           - has vpx gene [2]
The following cell types are infected in HIV infection
o CD4 T cells
o Dendritic cells
o Monocytes/macrophages
o Microglial cells
o Hofbauer cells
CD4  is a 55 k Dalton protein responsible for helper or inducer function of the immune system. 
It is also expressed on the surface of monocytes / macrophages and dendritic / langerhan cells.
Co receptors for HIV-1 infection are CCR 5 ( present on macrophages) & CXCR 4 (present on 
lymphocytes) [5]
Route Of Transmission [5]
• Mother to child transmission (MTCT)
• Blood , blood products, organ and tissue transplant.
• Intra venous drug abusers
• Sexual transmission
MTCT :  Commonest mode of HIV transmission in pediatric age group. With the perinatal 
period being the most vulnerable period for transmission of HIV infection
The various factors influencing transmission of perinatal HIV are
 High maternal viral load
 Prolonged rupture of membranes
 Sexually transmitted diseases during pregnancy
 Preterm delivery
 Obstetric procedures like episiotomy, amniocentesis
 Vitamin A deficiency
 Breast feeding
 Mastitis. 
 Oral thrush in the baby.
 Low maternal CD4 count
The  rate  of  perinatal  HIV  transmission  depending  on  maternal  viral  load  is  as  
follows:    
 <1000 copies/ml - Transmission rate is 0% 
 1000-10000 copies/ml - Transmission rate is 16.3%
 10001-50000 copies/ml - Transmission rate is 21.3%
 50001-100000 copies/ml - Transmission rate is 30.9%
 >100000 copies/ml- Transmission rate is 40.6%
Estimated risk and timing of MTCT [6] can be summarized as
 During pregnancy : 5-10%
 During labor and delivery : 10-15%
 During breast feeding : 5-20%
 Overall without breast feeding : 15-25%
 Overall with breast-feeding up to 6 months: 20-35%
 Overall with breast-feeding up to 18-24 months: 30-45%
Other body fluids such as saliva, tears, sweat and urine are not known to transmit HIV 
infection.  Saliva  contains  endogenous  antiviral  factor,  HIV  specific  immunoglobulins, 
secretory leucocyte protease inhibitor (SLPI) and submandibular gland saliva  strips gp120 of 
the  virus.  Hypotonicty  of  oral  secretions  further  causes  lysis  of  HIV  infected  cells. 
Transmission by human bite is rare but can occur.
Statergies for prevention of parent to child 
Transmission (PPTCT)
 Antiretroviral therapy
 Elective cesarean section when maternal viral load is more than 1000copies per ml
 Avoidance of breast feeding
 Prevention of other risk factors as given previously.
Spectrum Of HIV Infection [6]
 Primary HIV infection
Mucosal  dendritic cells binds the gp120 molecule of the virus and presents HIV to cells 
expressing  CD4 molecule.  Then  the  virus  is  transported  to  regional  lymph  nodes.  Intense 
replication of the viral genome occurs inside the cells and when it reaches critical level  burst of 
viraemia occurs. Dissemination of the virus then occurs, 3-6 weeks after infection characterized 
by flu like illness with fever, arthralgia, rash and lymphadenopathy. Host immunity against the 
virus then temporarily  suppresses the viral load to low levels and symptoms of acute viral 
disease disappear
 Chronic & Persistent infection 
Usually lasts for 8-10 years in adults. It is characterized by drop in the detectable free 
and cell associated virus in the blood with return of CD4 counts to almost normal level. During 
this period all  virologic parameters in the peripheral blood are very low. Hallmark of HIV 
infection is that it is never eliminated completely.
 Advanced HIV disease 
There is re emergence of free virus in both peripheral blood and lymph nodes with 
decline in CD4 counts and loss of function. There is emergence of faster replicating 
HIV. Disruption of lymphnode architecture and loss of dendritic cell network occurs 
with change of viral phenotype from NSI to SI (more virulent)
Mechanism of CD4 depletion and dysfunction.
 Direct damage by the virus.
 Immune mechanism triggered.
 Synctium formation induced by virulent strains eliminates hundreds of uninfected cells.
 Nonvirologic mechanism – autoimmune, anergy, super antigens, and apoptosis.
 Destruction of lymphoid.precursors
Natural  history  of  HIV  infected  (untreated)  has  three  distinct  patterns 
namely
• Rapid progressors - 15-25%. 
They  are  considered  to  be  infected  in  utero,  the 
immunocompetent  cells  are  infected  before  their 
migration from their site of origin, hence they have 
detectable virus  within first  48hrs  of  life.  They are 
symptomatic within first  few months of life  with a 
median survival of 6-9 months.
• Slow progressors - 60-80% 
They are considered to be infected intrapartum. Virus 
is  detectable  after  first  week of  life.  There  is  slow 
decline of viral load with a median survival of 6 years 
• Long term survivors - <5% 
They  are  considered  to  be  infected  during  breast 
feeding,  there  is  minimal  or  no  progression  of  the 
disease. They have relatively normal CD4  count and 
very  low  viral  load  for  longer  than  8  years.  They 
remain alive for more than 20 yrs [5].
Pediatric HIV : it is unique when compared to adult HIV in that the incubation period is 
shorter, there is hypergammaglobinemia with nonfunctional antibodies and B cell activation 
early in the course of infection. Oppurtunistic infections represent primary infection and are 
more severe and rapidly progressing. CNS involvement is more common.
Clinical staging of HIV infection by WHO guidelines [6]
Each stage is characterized with the following features
Primary HIV infection 
• Asymptomatic 
• Acute retroviral syndrome 
Clinical Stage 1
• Asymptomatic 
• Persistent generalized lymphadenopathy 
Clinical Stage 2
• Unexplained persistent hepatosplenomegaly
• Papular pruritic eruptions
• Extensive wart virus infection 
• Extensive molluscum contagiosum
• Recurrent oral ulcerations 
• Unexplained persistent parotid enlargement
• Linear gingival erythema 
• Herpes zoster 
• recurrent  or  chronic  respiratory  tract  infections  (otitis  media,  otorrhoea,  sinusitis, 
tonsillitis ) 
• Fungal nail infections
Clinical Stage 3
• Moderate unexplained malnutrition not adequately responding to standard therapy 
• Unexplained persistent diarrhea ( diarrhea lasting 14 days or more )
• Unexplained persistent fever ( temperature above 37.5 C intermittent or continuous, for 
longer than one month)
• Persistent oral candidiasis ( beyond first 6- 8 weeks of life)
• Oral hairy leukoplakia
• Acute necrotizing ulcerative gingivitis / periodontitis 
• TB lymphadenitis
• Pulmonary tuberculosis
• Severe recurrent presumed bacterial pneumonia 
• Symptomatic lymphoid interstitial pneumonitis
• Chronic HIV-associated lung disease including bronchiectasis
• Unexplained  anaemia  (  hemoglobin  <  8g/dl  ),  neutropenia  (<500/mm3)  or  chronic 
thrombocytopenia (<50 000/ mm3)
• HIV-associated cardiomyopathy or HIV-associated
•  nephropathy (u
• nexplained )
Clinical Stage 4
• Unexplained severe wasting, stunting or severe malnutrition not responding to standard 
therapy
• Pneumocystis pneumonia
• Recurrent severe presumed bacterial infections  (e.g. empyema,  pyomyositis, bone or 
joint infection, meningitis, but excluding                         pneumonia)
• Chronic  herpes  simplex  infection  (orolabial  or  cutaneous  of  more  than  one month's 
duration or visceral herpes at any site) 
• Extrapulmonary tuberculosis 
• Kaposi sarcoma
• Oesophageal candidiasis or candidial infection of trachea, bronchi or lungs
• Central nervous system toxoplasmosis ( beyond the neonatal period)
• HIV encephalopathy
• Cytomegalovirus (CMV) infection; retinitis or CMV infection affecting another organ, 
with onset at age over 1 month.
• Extrapulmonary cryptococcosis including meningitis
• Disseminated  endemic  mycosis  (extrapulmonary  histoplasmosis,  coccidiomycosis, 
penicilliosis)
• Chronic cryptosporidiosis
• Chronic isosporiasis
• Disseminated non-tuberculous mycobacteria infection 
• Acquired HIV-associated rectal fistula 
• Cerebral or B cell non-Hodgkin lymphoma
• Progressive multifocal leukoencephalopathy.
Tests for diagnosis of HIV infection 
•HIV Antibody Test
•HIV viral culture
•HIV immune complex dissociated (ICD) p24 antigen test
•HIV DNA PCR
Recommendations for HIV diagnosis in < 18 months of Age:
• Definitive diagnosis of HIV infection only by virological testing 
• Confirmation  of  HIV  infection  by  two  positive  virological  tests  done  on  separate 
specimens
• If a single positive virological test is to be considered diagnostic in a symptomatic infant 
due to resource constraints, HIV antibody testing should be done after 18 months of age 
to confirm the diagnosis
Clinical criteria for presumptive diagnosis of severe HIV disease in infants and children 
< 18 months of age
 A presumptive diagnosis of severe HIV disease should be made if the infant is confirmed as 
HIV antibody positive
 and diagnosis of any AIDS-indicator condition(s) can be made or
 the infant is symptomatic with two or more of the following oral thrush, severe pneumonia and 
severe sepsis
HIV Diagnosis In A Breast- Feeding Infant•
• A negative virological test does not rule out HIV infection in the infant who is breast-
feeding
• Virological testing should be done 6-8 weeks after complete cessation of breast-feeding
• If infant is older than 9 months at the time of stopping breast-feeding, do HIV ELISA 
first, if negative, no need to do virologic test
• If negative virologic test or negative HIV ELISA after 9-12 months, confirm absence of 
infection with a negative ELISA after 18 months
Recommendations for HIV diagnosis in >  18 months of Age: 
• Definitive diagnosis using HIV antibody tests.
• A positive test  should be confirmed by a second positive antibody test on the same 
specimen using a different assay technique.
HIV DIAGNOSIS IN > 18 MONTHS OF AGE:
 
BREAST- FEEDING
CHILD
NON BREAST- FEEDING
CHILD
HIV ANTIBODY TESTHIV ANTIBODY TEST
CONFIRMED POSITIVE TESTNEGATIVE TESTCONFIRMED POSITIV  TEST NEGATIVE TEST
 RETEST AFTER 
6 WEEKS OF STOPPING
BREAST- FEEDING
NOT HIV
INFECTED
HIV
INFECTED
CONFIRMED POSITIVE 
TEST
NEGATIVE TEST
HIV
INFECTED
NOT HIV
INFECTED
REFER FOR TREATMENT
FLOWHIV DIAGNOSIS IN < 18 MONTHS OF AGE: 
BREAST- FEEDING
INFANTNON BREAST- FEEDING
INFANT
VIROLOGIC TESTING
AT 6 WEEKS
VIROLOGIC TESTING
AT 6 WEEKS
POSITIVE TEST NEGATIVE TEST NEGATIVE TESTPOSITIVE     TEST
 RETEST AFTER 
6 WEEKS OF STOPPING
BREAST- FEEDING
NOT HIV
INFECTED
REPEAT POSITIVE TEST
NEGATIVE TESTPOSITIVE TEST
NOT HIV
INFECTED
HIV
INFECTED
HIV
INFECTED
REPEAT POSITIVE TEST
Guidelines to start antiretroviral therapy [5]
WHO clinical stage 4 - treat all irrespective of age and CD4 counts
WHO clinical stage 3 - <12 months of age - treat all irrespective of 
age and CD4 counts.
- > 12 months of age – treat all except CD4 guided in cases of 
TB,  Oral  hairy  leukoplakia,  lymphoid  interstitial 
pneumonitis.
WHO clinical stage 1 and 2 - based on CD4 counts.
Highly Active Antiretroviral Therapy [1]
The various classes of drugs used in the treatment of AIDS are grouped as follows:
 Nucleoside Reverse Transcrtiptase Inhibitors (NRTI)
They  are  purine  or  pyrimidine  analoges,  which  after  modification  in  the  cell  (eg:- 
phosphorylation)  selectively  inhibits  the  viral  reverse  transcriptase. 
Thus the viral single stranded RNA is not converted to double stranded viral DNA and hence 
viral replication is halted. 
The various drugs in this group commonly used are
Zidovudine   (AZT)
       REPEAT VIROLOGICAL TESTING IF INFANT BECOMES SYMPTOMATIC
Stavudine      (d4t)
Didanosine    (ddl)
Abacavir        (ABC)
Emtricitabine (FTC)
Lamivudine    (3TC)
Tenofovir        (TDF)
The common adverse effects of this class of drugs are
Zidovudine - Bone marrow suppression, myopathy, hepatomegaly
Lamivudine - headache, GI intolerance
Stavudine - headache, rash, peripheral neuropathy, pancreatitis. lactic 
acidosis
Abacavi - Lactic acidosis, GI intolerance, hepatomegaly  elevated 
triglycerides
 Non Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
These  are  nucleoside  unrelated  compounds  which  directly  inhibit  HIV– 
reverse  transcriptase  enzyme  without  the  need  for  intracellular 
phosphorylation                                                                                                                       
The drugs in this group are
Nevirapine (NVP)
Efavirenz (EFV)
The  class  side  effects  are  rash,  muscle  involvement  and  elevated  liver 
Enzymes in addition efavirenz may produce CNS and neuropsychiatric symptoms
 Protease Inhibitors (PI)
The aspartate protease enzyme encoded by HIV is involved in the production of the 
structural  proteins  and  enzymes,  this  last  step  in  HIV 
replication  is inhibited by this class of drugs. 
The common drugs used in this group are
Nelfinavir          - (NFV)
Ritonavir           - (RTV)
Lopinavir          - (LPV)
Saquinavir        -  (SQV)
Amprenavir      - (APV)
The class side effects of these drugs are hyperglycemia, hyperlipidemia, lipodystrophy, 
increased liver enzymes and increased bleeding disorders in hemophiliacs.
 Fusion Inhibitors
This group of drugs bind to viral gp41, which prevents fusion of the virus with the CD4 
cell  and  hence  entry  of  the  virus  into  the  cell.  The  only  drug  approved  in  this  group  is 
enfuviritide with common adverse effect of local injection site reactions. 
First Line Regimen
Regimen  of  2  Nucleoside  Reverse  Transcriptase  Inhibitor  plus  1  Non  Nucleoside 
Reverse Transcriptase Inhibitor. Eg:- 
Zidovudine + Lamivudine + Nevirapine or Efavirenz
Stavudine + Lamivudine + Nevirapine or Efavirenz.
Abacavir + Lamivudine + Nevirapine or Efavirenz.
Second Line Regimen
Regimen  of  2  Nucleoside  Reverse  Transcriptase  Inhibitor  plus  1  Protease  inhibitor 
( Ritonavir, Lopinavir, Nelfinavir)
LITERATURE REVIEW
Rosemary, et al  from Centre Hospitalier de Kigali, Rwanda, Africa did a prospective 
cohort study done from November 1988 to June 1994 [8]. In the study 218 children born to 
HIV-1-seropositive mothers and 218 born to seronegative mothers  of the same age and parity 
were followed up for 5yrs. Except for 4 babies of HIV positive mothers all others were breast 
fed upto 18 months and all were immunized upto 15 months of age. 
The following conditions were regarded as HIV-related namely chronic diarrhea ( >14 
days), chronic cough ( >14 days), chronic fever ( >14 days), severe or recurrent pneumonia, 
hepatosplenomegaly, generalized dermatitis, lymphoid interstitial pneumonitis, oral candidiasis 
(beyond the neonatal period), chronic parotitis, persistent generalized lymphadenopathy (lymph 
nodes measuring > 0.5 cm and present in two or more extra inguinal sites),  failure to thrive (< 
80% of weight for age). 
Of the 218 children born to HIV positive mothers, 54 were diagnosed as HIV positive. 
The remaining 35 children, born to seropositive mothers, had an indeterminate infection status 
and  were  excluded  from  the  following  analysis.  A  total  of 347 children  were  considered 
uninfected,  of  which  138 were  born  to  HIV-infected women  and  209 to  HIV-uninfected 
women.
Comparisions between uninfected children born to seropositive women and uninfected 
children born to seronegative women showed that these two groups did not differ with respect 
to mortality during the 5 years  of follow-up (Cox hazard ratio [HR] = 0.4, 95% confidence 
interval [CI] =  0.1-1.6; p = 0.20). 
Morbidity  pattern  among  uninfected  HIV  exposed  and  unexposed  infants  were 
comparable. All though severe pneumonia,  generalized dermatitis and chronic parotitis  were 
more in the HIVexposed children it was not statistically significant (p = 0.12). 
The initial clinical signs that occurred most frequently in the HIV infected were failure to 
thrive  (51.9%)  and  persistent  lymphadenopathy  (44.4%).  The  most  frequent  signs  among 
infected children were chronic cough (97%), persistent generalized lymphadenopathy (93%), 
and failure to thrive (92%). 
All of the HIV symptomatic conditions studied also occurred among uninfected children, 
although the risk of onset among uninfected children was significantly lower (3 - 13 times) than 
among infected children, except for chronic cough, which occurred in almost all of the children, 
regardless of their HIV infection status. Recurrent oral candidiasis and chronic parotitis had the 
greatest ability to discriminate infected from uninfected children ( 20 times more frequently in 
infected than in uninfected children).
Twenty-eight  (52%)  infected  children  and  13 (4%)  uninfected  children  died  during 
follow-up. 
Among the 28 infected children who died, 9 met the case definition of AIDS.  
The probability of death in infected children was 0.62 (95% CI: 0.47-0.78) at  5 years of 
age. 
The estimated cumulative probability of death in uninfected children was 0.04 (95% CI: 
0.02-0.07) at 5 years of age. The overall risk of death was 20.7 times higher in infected children 
than in uninfected children (95% CI:  10.7-40.0).  Median age at death was 13.4 months for 
infected and 7.7  months for uninfected children). The most common causes of death among 
infected children were pulmonary infections (9 cases) and diarrhea (8 cases). 
Increased risk of death observed in 
a) an early HIV infection before 3 months of age (relative hazards of death: 10.3)
b) Short interval ( < 6 months) between HIV  infection and occurrence  of the first HIV-
related conditions (relative hazards of death: 5.4)
c) Failure to thrive as the initial pattern of clinical HIV disease (p = 0.07) 
Decreased risk of death - chronic diarrhea, splenomegaly, or chronic parotitis (HR: 0.2, 0.3, and 
0.1, respectively).
The maternal CD4 cell count and the child's CD4 / CD8 ratio at 6 months of age was not 
predictive of death.
Of the 54 HIV infected children, 14 (26%) developed AIDS, according to the modified 
WHO clinical definition.
Increased risk of clinical AIDS 
1) by 15 times if initial presentation was persistent generalized lymphadenopathy (95% CI: 
3.1-73.9)
2) by 4.7 times if initial presentation was failure to thrive (95% CI: 1.4-16.1)
Decreased risk of developing AIDS - lymphoid interstitial pneumonitis during the course of the 
disease (HR: 0.04; 95% CI: 0.01-0.4) 
Age at infection, interval between infection and onset of the first HIV-related conditions, 
and maternal and children biological characteristics were not associated with the subsequent 
development of clinical AIDS.
Ryder, et al from Kinshasa hospitals, Zaire.Africa did a prospective cohort study during 
December 1986 to April 1987 [9] which analyzed 475 infants of 466 seropositive women and 
the 616 infants of 606 seronegative women matched for age, parity. Of the 466 seropositive 
women, 85 (18%) had AIDS manifestations. The neonatal mortality among HIV exposed and 
unexposed were 29 (6.2%) and 8 (1.2%) respectively, p<0.0001. The infants of seropositive 
mothers, as compared with those of seronegative mothers, had lower birth weights (p < 0.01). 
Out of the 92 children with complete follow-up 36 (39%) were HIV positive. At one year, 99 
(21%) infants to HIV seropositive mothers had died as compared with 23 (3.8%)born to HIV 
seronegative mothers (p < 0.001).  Of the remaining surviving infants born to HIV positive 
mothers 29 (7.9%) had clinical AIDS.
Blanche, et al did a French collaborative study [10]. A total of 308 babies born to 308 
HIV seropositive  mothers  were  followed-up.  Of  the  308 mothers  only  one  had  symptoms 
accompanying seroconversion, all others were asymptomatic. Twelve percent of the children 
were delivered by cesarean section. At 18 months of age 117 children were tested for HIV, of 
which 32 (27%) were HIV positive. Of the 85 seronegative children, 9 (8%) had clinical signs 
related  to  HIV  infection  such  as  hepatosplenomegaly,  lymphadenopathy.  There  was  no 
difference in birth weight, length or head circumference between HIV infected and uninfected 
infants. Five of the six infants (83 %) who were breast fed were infected when compared to 25 
of 99 (25%) bottle-fed infants p < 0.01. 
Gail, et al from Bronx and Brooklyn (U.S.A) [11] has observed  that HIV seropositive 
mothers had more sexually transmitted diseases than seronegative mothers (17.6% vs. 7.1%). 
Only  3% of  HIV  seropositive  had  AIDS symptoms.  Other  obstetrical  complications  were 
comparable  between  HIV positive  and  negative  mothers.  HIV seropositive  mothers  had  a 
higher rate of medical complications when compared to HIV negative mothers (43% vs. 25%). 
Infant  factors  at  birth  such as  birth  weight,  gestational  age,  head circumference and apgar 
scores were similar in both HIV exposed and unexposed babies. The author concludes that HIV 
infection in the absence of AIDS symptoms does not appear to be associated with negative 
pregnancy or neonatal outcomes.  
Bal Runa, et al from West Bengal [12] stated that based on the observations in PPTCT 
centers in West Bengal the prevalence of HIV infection among antenatal mothers was 0.11%. 
Maternal records of 49 such mothers were obtained of which 95.34% of mothers delivered 
vaginally and 88.37% of the outcomes of pregnancy were live born. Only 11 babies of the total 
38 live born attended the 18 month follow- up, 2 of them were detected to be HIV positive.
Rashid, et al from Mumbai.[13] did a study with 1724 HIV positive mothers. Of them 
only 43.6% of mothers took Zidoviduine prophylaxis for prevention of perinatal transmission 
of HIV. Of the 1724 mothers, 82% delivered vaginally and 18% underwent cesarean section for 
obstetric reasons. Counseling regarding feeding options were given and 78% opted for artificial 
feeds. The mother to child HIV transmission rate was 10.1%. 
Adhikari, et al from Department of Pediatrics, Nelson R Mandela school of Medicine, 
Durban  South Africa [14] had shown that the prevalence of HIV-1 infection among women 
attending the King Edward Hospital, Durban South Africa was 30% in 2001. Out of the 11084 
babies born to HIV positive mothers admitted in neonatal unit during the period of study, 23% 
were  classified  as  low birth  weight.  Of  the  total  babies  476 infants  born  to  HIV positive 
mothers were followed up, their maternal HIV status were as follows.
Mothers tested antenatally - 445 (93%)
Mothers tested postnatally – 33 ( 7%)
Only  308  infants  attended  follow  up  clinics,  out  of  which  only  85/476babies  were 
testsed at 15-18 months for HIV infection, the results were as follows:
Number of babies tested positive by HIV ELISA and or PCR - 24 (28%) Out of 302 
infants  followed  up,  192  (64%)  had  physical  sign  suggestive  of  HIV  infection  such  as 
hepaatomegaly, splenomegaly, significant lymphadenopathy, monilial infection of skin/mouth/
perineum,  seborrheic  dermatitis  or  pneumonia.   Most  of  the  infants  with  physical  signs 
suggestive of HIV infection had transient  signs 73 (38%) or persistent signs but resiolving 
within 12 months 97 (43%). Only 22 (19%) babies had persistent signs not resolved by 12 
months, all of them tested positive for HIV infection at 18 months of age.  Among the HIV 
exposed infants with persistent signs co-infectious were diagnosed in 69 (59%)  which were 
Tuberculosis in 57 babies,  CMV in 8 babies,   syphilis in 2 babies and Herpes Zoster in 3 
babies.  Only 12 of these infants were tested HIV positive at 18 months of age.  So early signs 
suggestive of HIV infection did not predict HIV status of an infant at 18 months of age.
Major Prospective Trials Of Anti Retroviral Therapy 
To Prevent Perinatal HIV Transmission
Study Site Breast feeding
Arm
(n)
Antiretroviral regimen
Ante-
partum
Intra-
partum
Post-partum
Trans-
mission 
%
p
PACTG 07615 USA No A (205) ZDV at 
>14 weeks
ZDV ZDV for 6 
weeks
8.3 0.00006
B (204) placebo placebo placebo 25.5
PACTG 18516 USA No A (230) as per 
primary 
care + 
HIVIG
ZDV ZDV + HIVIG 4.1 NS
B (224) as per 
primary 
care + 
IVIG
ZDV ZDV + IVIG 6.0
Thai17 Thailand No A (198) ZDV at 36 
weeks 
ZDV none 9.4 0.006
B (199) placebo placebo none 18.9
Cote d'lvoire18 Cote 
d'lvoire
Yes A (140) ZDV at 36 
weeks 
ZDV none 15.7 0.07
B (140) placebo placebo none 24.9
DITRAME19 Cote 
d'lvoire 
Yes A (203) ZDV at 36 
weeks 
ZDV ZDV to 
mother for 7 
days
18.0 0.028
B (211) placebo placebo none 27.5
PETRA20 South 
Africa
Yes A (359) ZDV + 
3TC at 
≥36 weeks
ZDV + 
3TC
ZDV + 3TC to 
mother and 
child for 7 
days 
8.6 0.001
B (343) placebo ZDV + 
3TC
ZDV + 3TC to 
mother and 
child for 7 
days 
10.8
C (351) placebo ZDV + 
3TC
placebo 17.7 0.02
D (351) placebo placebo placebo 17.2
HIVNET21 Uganda Yes A (302) none ZDV ZDV to child 
for 7 days
25.1 0.0006
B (307) none NVP NVP to child 
single dose
13.1
ZDV - Zidovudine to mother 100 mg po five times per day.
ZDV - Zidovudine at labor - 2 mg/kg iv x 1, then 1 mg/kg iv 
every hour  in labour.
ZDV - Zidovudine to baby - 2 mg/kg po every 6 h to child for 6 
weeks beginning 8–12 h after birth.
IVIg - Immunoglobulin dose 200 mg/kg iv every 4 weeks from 
20–30  weeks' gestation until delivery.
Immunoglobulin- 200 mg/kg iv to child within 12 h of birth.
3TC - Lamivudine to mother - 2 mg/kg po every 12 h.
NVP - Nevirapine to mother -200 mg po x 1 at onset of labour.
NVP - Nevirapine to baby -2 mg/kg oral suspension  within 72 
hrs after birth, with additional dose immediately after birth to any child 
whose mother did not receive the intra-partum dose or received it <1 h 
before delivery.
STUDY JUSTIFICATION
India along with Africa share the major burden of HIV/AIDS cases but there  are only 
limited studies on the outcome of children born to  HIV positive mothers especially in South 
India.  The  various  articles  have  conflicting  results,  varying  duration  of  study  and  varying 
PPTCT  methods  hence  lacking  uniform  results.   Such  a  study  is  important  to  know  the 
morbidity and mortality patterns in the early years of HIV exposed children. 
AIM
To Study the outcome of children born to HIV positive mothers in terms of morbidity, 
mortality and HIV status at follow-up up to 18 months of age.
SUBJECTS AND METHODS
METHODOLOGY
STUDY DESIGN: Cohort
STUDY PLACE 
Institute of Obstetrics and Gynecology, Chennai
           Institute of Child Health and Hospital for 
children, Chennai
            STUDY PERIOD: Oct 2006 to Oct 2008
POPULATION
Study Cohort- 50 Babies born to HIV sero positive Mothers.             
           Control Cohort- 100 Babies born to HIV sero negative Mothers.
MANOEUVRE
The study was conducted in  the Institute  of Obstetrics  and Gynecology,  Institute  of 
Child Health and Hospital for children, Chennai. Fifty babies born to HIV positive mothers and 
100 babies born to HIV negative mothers were enrolled in the study from the post-natal ward, 
after obtaining consent for participation in the study. Immediately after birth the newborn were 
given single dose of syrup. Nevirapine  2 mg/kg per oral. Maternal details were obtained from 
their  case  records.  Maternal  morbidity  pattern  were  compared  between  HIV  positive  and 
negative mothers. The mothers were detected as HIV positive either previously or ante-natally, 
they were started on HAART (highly active anti retro viral therapy) based on clinical  and 
laboratory parameters. Comparision of various maternal parameters were done between HIV 
positive and negative mothers. The maternal morbidities analyzed were 
Anemia – defined as hemoglobin concentration <11 gm/100ml.
PIH – defined as blood pressure more than 140/90 mmHg and proteinuria detected after 
20 weeks of gestation in a previously normal woman.
GDM – defined as abnormal carbohydrate tolerance with onset or first detected during 
pregnancy as evidenced by abnormal glucose tolerance test.
Wasting – pre pregnancy weight and height less than 45 kg and 145 cms respectively [4] 
At the onset of labor the mothers were given a single dose of tablet Nevirapine 100mg 
or HAART continued if already on it.. The mode of delivery was labor naturalis with minimum 
intervention.  Cesarean section was done only for  obstetric  reasons  such as cephalo-  pelvic 
dispropotion,  prolonged  rupture  of  membranes,  fetal  distress,  cord  around  neck,  fetal 
malpositions and non progression of labor. If the antenatal mothers were on HAART, their 
newborns were given  syrup. Zidovudine-2mg/kg/day in five divided doses for six weeks. 
The mothers were counseled about feeding options
       a) Exclusive replacement feeds
       b) Exclusive breast feeding for four months, abrupt stopping and 
            starting replacement feeds.
At  birth  the  neonates  were  evaluated,  anthropometric  measurements,  congenital 
anomalies and other vital  parameters  were noted down. The newborns requiring care were 
admitted in the New born ward and necessary 
management done. The birth weight and neonatal morbidity were compared between babies 
born to HIV positive and negative mothers, the 2 groups of babies were further referred to as 
HIV exposed and unexposed babies. 
Infants  were  categorized as adequate for  gestation age (AGA) and low birth  weight 
(LBW) [1] based on weight more than 2.5 kgs and less than 2.5  kgs respectively.   
The next visit scheduled was after 6 weeks, when cotrimazole prophylaxis was started 
for all infants. Syrup. Cotrimoxazole was given at a dose of 5 mg/kg/day The babies were then 
followed  up  every  three  months  and  at  each  visit,  their  growth  and  development  was 
monitored, feeding problems were evaluated. Treatment of common ailments, nutrition advice 
and management were done as required. They were also evaluated for HIV related diseases. 
The infants  were categorized based on weight as 
normal  nutritional  status  and  under  nourished 
( under nourished defined as weight below the 3rd 
perrcentile of WHO growth charts)
All the babies were assessed for developmental delay using Trivandrum screening test 
and  classified  as  with  normal  development  and  developmental  delay.  The  infants  with 
developmental delay were further evaluated by Neurologist  and management carried out as 
suggested. Specialists opinion such as physiotherapist, audiologist were sorted as required.
The infections,  illnesses and congenital anomalies were tabulated for both groups of 
babies and comparisions were made. 
The HIV status of infants was determined by HIV RNA - PCR , and at 18 months of age 
by ELISA for HIV antibodies. Cotrimoxazole prophylaxis was stopped after HIV status was 
determined as negative.The mortality patterns in both groups were analysed.
STATISTICAL ANLYSIS
Proportions of various outcome measures were arrived at. 
All  the outcome variables were compared between babies born to HIV positive and 
negative mothers.
The various outcome variables were compared between HIV exposed and unexposed 
babies by using the following tests:
Chi  square  test  and  two  sample  binomial  propotion  test  were  used  to  analyse  the 
significance of association between HIV exposure and categorize outcome measures. 
Relative risk (RR) with 95% confidence interval [CI] was determined.
The mean episodes and standard deviation of illnesses were compared by using student t 
test and significance of differences were computed by determing the p value. A p- value of < 
0.05 was considered as significant.
RESULTS
 Comparision of Birth Weight Among HIV Exposed and Unexposed Babies
Fifty babies born to HIV positive mothers and 100 babies born to HIV seronegative 
mothers were followed up from birth to 18 months of age. Among the 50 HIV exposed babies, 
7  (14%)  were  low birth  weight  and  43  (46%)  were  appropriate  for  gestational  age  when 
compared to 12 (12%) of low birth weight babies and 88 (88%) of appropriate for gestational 
age babies among HIV unexposed.  
HIV exposed babies were found to be 1.17 times at  risk for low birth weight when 
compared to HIV unexposed babies, but it did not achieve statistical significance [RR:1.17 with 
95% CI = (0.52 – 2.7) and p = 0.72]  [Table 1].  
Table: 1 Comparision of birth weight and HIV exposure
HIV EXPOSURE
STATUS
BIRTH WEIGHT
LBW
n (%)
AGA
n (%)
EXPOSED 7 (14%) 43 (86%)
UNEXPOSED 12 (12%) 88 (88%)
where AGA is appropriate for gestation age and LBW is low birth weight 
 Comparision of mode of delivery among HIV exposed and unexposed babies
Mode  of  delivery  was  compared  among  HIV  exposed  and  unexposed  babies  and 
categorized as labor naturalis (LN) or caesarean section. The results were as follows:
Of the 50 HIV exposed babies, 24 (48%) were delivered by cesarean section and 26 
(52%) were delivered by labor naturalis when compared to 42 (42%) and 58 (58%) respectively 
among HIV unexposed. 
HIV exposed babies were found to be 0.88 times delivered by cesarean  section when 
compared to HIV unexposed babies, but it did not get statistical significance [RR:0.88 with 
95% CI = (0.6 – 1.27) and p = 0.48] [Table 2]. 
Table: 2 Comparision of mode of delivery and HIV status of mothers
HIV EXPOSURE
STATUS
MODE OF DELIVERY
CESAREAN
n (%)
LN
n (%)
EXPOSED 24 (48%) 26 (52 %)
UNEXPOSED 42 (42%) 58 (58%)
where:  LN – labor naturalis.
 Comparision of neonatal morbidity among HIV exposed and unexposed
At birth  out  of  the  50  babies  born  to  HIV positive  mothers  only  3  babies  required 
admission. The reason were as follows:
• The first baby was born preterm of approximate gestational age of 34-      36 weeks and 
2 kgs. The baby was asphyxiated at birth with a Apgar score of 2/10, 5/10 and 5/10 at 
1minute, 2minutes and 5 minutes respectively. The baby was admitted in the medical 
newborn ward. Baby developed respiratory distress at 7 hours of life and radiological 
picture was that of hyaline membrane disease. Baby was conservatively managed with 
oxygen, intravenous fluids and antibiotics. Baby condition improved, respiratory distress 
settled and started on nasogastric feeds. After 10 days of stay direct breast feeds were 
started and baby was discharged at 14 days of life. There was no neurological sequelae 
at discharge.
• The second baby was born preterm of approximate gestational age of 32 – 34 weeks and 
1.3 kgs. The baby had intra uterine growth retardation and was started on intra venous 
fluids.  Investigations  were  normal  except  for  low  serum  calcium  level  which  was 
promptly treated with calcium supplements. The calcium levels repeated after 5 days 
were  normal.  Baby  was  hemodynamically  stable  through  out  hence  gradually 
started on expressed breast milk feeds (as per mother’s choice) and     then direct breast 
feeds. Baby was discharged after 18 days of hospital          stay with intact neurological 
function
• The third baby was born through meconium stained liquor and was non vigorous, baby 
established respiration after two cycles of bag and           mask ventilation. The baby was 
low birth weight and developed respiratory distress. The radiological picture was that of 
meconium aspiration syndrome.Baby was managed with oxygen, intra venous fluids and 
intra venous antibiotics. Baby improved , respiratory distress setlled and was weaned 
from oxygen.  Baby  was  started  on  replacement  feeds  (as  per  mother’s  choice)  and 
discharged after10 days.
Of the 100 babies born to HIV negative mothers , 8 required admissions, the diagnoses 
were as follows:
• Preterm care (PT) – 2
The first baby was born at an estimated gestational age of 32-34 weeks and 1.6 kgs. 
Baby was admitted in the medical newborn unit and was started on intravenous fluids and 
supplementary  oxygen  for  mild  respiratory  distress.   
The blood investigations were within normal limits  and chest  radiograph was also normal. 
Baby improved with treatment and respiratory distress settled after 3 days.  Baby was started 
on nasogastric tube feeds and gradually weaned to direct breast feeds in the next two weeks and 
discharged from hospital.
The second baby was admitted as borderline preterm (estimated gestational age of 36-37 
weeks) and low birth weight (1.8 kgs).  Baby was given expressed breast milk and then started 
on direct breast feeds and discharged after 4 days of hospital stay.
• Early onset Sepsis (EOS) – 2
The two babies born to mothers with prolonged rupture of membranes          (duration of 
rupture of membranes more than 24 hours) were admitted for evaluation of early onset sepies. 
The first baby was asymptomatic, the septic screen was negative and hence discharged on day 
3 of life.  The second baby developed respiratory distress at 10 hours of life. The baby was 
investigated, chest radiolograph revealed Bronchopnemonia and septic screen was negative. 
The baby was given iv antibiotics for 7 days respiratory distress settled and was discharged on 
direct breast feeds.
• Birth asphyxia (BA) – 2
Both babies were born by cesarean section for intrapartum fetal distress (as evidenced 
by  fetal  bradycardia).  The  first  baby  was  resuscitated  with  two  cycles  of  Bag  &  Mask 
ventilation and admitted into medical newborn with respiratory distress.  Baby had convulsions 
on day 1 of  life which was managed with iv fluids, intravenous Phenobarbitone injection.  The 
blood investigations and radiographic investigations were normal.   The baby developed no 
further convulsions and general condition improved.  Tube feeds were started on day 4 and the 
baby improved and was discharged after 8 days of stay.  The second baby was also resuscitated 
with 2 cycles of Bag & Mask ventilation and admitted into medical newborn with respiratory 
distress and lethargy.  The blood investigations and chest radiograph was normal.  The baby 
improved and intravenous fluids were tapered, breast feeds established and discharged after 6 
days of stay.
• Meconium aspiration syndrome (MAS) – 1
Baby was born by labor naturalis with meconium stained liquor.  The baby was vigorous 
and admitted for mild respiratory distress.  The respiratory distress settled by 12 hours of life, 
hence supplementary oxygen and intravenous fluids were stopped and breast  feeds  started. 
Baby  was  discharged  at  day  4  of  life  after  septic  screen,  blood  biochemistry  and  chest 
radiograph were normal.
• Intra uterine growth retardation (IUGR) – 3
All the three babies were Term / IUGR babies (birth weight was less than 1.8 kg ), they 
were started on expressed breast feeds and investigated for metabolic abnormalities.  All the 
investigations were normal and the babies were successfully started on direct breast feeds and 
discharged from hospital [Figure 1].
Figure 1 : Neonatal morbidities among HIV exposed and unexposed babies
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where X-axis is number of newborns.
Out  of  the  50  HIV  exposed  babies  at  birth  3(6%)  required  admission  with 
neonatal morbidity when compared to 8(8%) of HIV exposed babies requiring admission, 
which was comparable between the groups (p = 0.65).
 Comparision of medical illness among HIV positive and negative mothers 
Common maternal  illnesses  such  as  anemia,  pregnancy induced hypertension  (PIH), 
gestational diabetes (GDM) and wasting were compared between HIV positive and negative 
mothers.
Maternal anemia was found to be more common in HIV positive mothers  (82%) than in 
HIV negative mothers (61%), (p = 0.009).
Similarly wasting was found to be more common in HIV positive mothers  (12%) than 
in HIV negative mothers (1%), (p = 0.009).
Table: 3 Comparision of medical illness among HIV positive and negative mothers
MATERNAL
ILLNESS
HIV STATUS
POSITIVE
n (%)
NEGATIVE
n (%)
STATISTICAL
SIGNIFICANCE
P value
ANEMIA 41 (82%) 61 (61%) O.009
PIH 2 (4%) 5 (5%) 0.89
GDM 0 (0 %) 1 (1%) 0.72
WASTING 6 (12%) 1 (1%) 0.009
Among the HIV positive mothers, 2(4%) had pregnancy induced hypertension which 
was  comparable  to  the  5(5%)   of  HIV  negative  mothers  who  had  pregnancy  induced 
hypertension, (p = 0.89). 
On comparing the mothers for gestational diabetes none of the HIV positive mothers had 
gestational diabetes where as 1(1%) HIV negative mothers had gestational diabetes which did 
not have statistical significance (p = 0.72) [Table 3].
 Clinical status of HIV positive mothers:
No of antenatal mothers living with HIV/AIDS – 50
No of mothers antenatally detected as HIV positive and asymptomatic –32(64%)
No of mothers previously detected and asymptomatic – 10(20%)
No of mothers with clinical AIDS and on HAART (highly active anti retroviral therapy) 
– 8(16%) [Figure 2].
Figure 2 : Status of HIV positive mothers
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 Comparision of antiretroviral drugs used for prevention of perinatal transmission of HIV 
Total number of babies born to HIV positive mothers – 50
No. of mothers at labor and babies given single dose Nevirapine–42 (84%)
Number of babies given six weeks of Zidovudine – 8(16%)
 Breast feeding options among HIV positive babies
Among the 50 HIV positive mothers their feeding options at birth were as follows: 
• Exclusive  breastfeed  for  4  months  and  then  started  on  replacement  
feeds – 36(72%)
• Exclusive replacement feeds – 12(24%)
• Mixed feeding – 2(4%)
Among the HIV negative mothers only 2(2%) never breast fed [Figure 3].
Figure 3 : Feeding options among HIV positive mothers at birth:
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BF  breast-feeds,  RF  replacement  feeds,  MIXED  both  breast-feeds  and  replacement 
feeds
Among the HIV positive women, only 2(2%) breast fed beyond 4 months of age when 
compared to 93(93%) of the HIV negative mothers who breast fed beyond 4 months of age.
HIV positive mothers were more likely to choose replacement feeds and shorter duration 
of  breast-feeding,  when  compared  to  HIV  negative  mothers  
(p = 0.001) [Table 4].  
Table: 4 Comparision of duration of breastfeeding among HIV exposed and unexposed 
babies
HIV
EXPOSURE
STATUS
DURATION OF BREAST FEEDING
NIL
n (%)
UPTO 4 
MONTHS
n (%)
4 TO 6
MONTHS
n (%)
MORE 
THAN
6 MONTHS
n(%)
EXPOSED 12 (24%) 36 (72%) 2 (4%) 0 (%)
UN EXPOSED 2 (2%) 5 (5%) 23 (23%) 70 (70%)
 Observations  on  follow  up:  Comparision  of  development  among  HIV  exposed  and 
unexposed babies
All the babies were assessed for developmental delay using Trivandrum screening test. 
Out of the 2 babies with developmental delay in HIV exposed group the first baby had perinatal 
asphyxia and Cerebral palsy , the second baby had seizure disorder controlled by antiepileleptic 
medication.
Among HIV unexposed 3 babies had developmental delay, the diagnosis of the babies 
were  Cerebral  palsy  with  spastic  quadriparesis,  global  developmental  delay  with  mental 
retardation and Dandy walker syndrome.
Table: 5 Comparision of development among HIV exposed and unexposed babies
HIV
EXPOSURE
STATUS
DEVELOPMENT
DELAY
n(%)
NORMAL
n(%)
EXPOSED 2 (4%) 48 (96%)
UN EXPOSED 3 (3%) 97 (97%)
HIV exposed babies were found to be 1.33 times at risk for developmental delay when 
compared to HIV unexposed babies, but it did not achieve statistical significance. 
[RR: 1.33 with 95% CI = (0.52 – 2.7) and p = 0.74].  
 Comparision of nutritional status among HIV exposed and unexposed babies
Among the HIV exposed babies 5(10%) had under nutrition when compared to 9(9%) of 
the HIV unexposed babies. HIV exposed babies were found to be 1.1 times more at risk for 
under  nutrition  when  compared  to  HIV  unexposed  babies  but  the  difference  was  not 
statistically significant. 
[RR:1.1 with 95% (CI 0.4 – 3.1) and p = 0.84] [Table 6].
Table: 6 Comparision of nutritional status among HIV exposed and unexposed babies
HIV
EXPOSURE
STATUS
NUTRITION
UNDER
n(%)
NORMAL
n(%)
 EXPOSED 5 (10%) 45 (90%)
UN  EXPOSED 9 (9%) 91 (91%)
 Comparision  of  major  illness  and  congential  anomalies  among  HIV  exposed  and 
unexposed babies
Among the HIV exposed 2 babies had major illness or congenital anomalies namely 
seizure disorder and Cerebral palsy.
Among the HIV unexposed 5 babies had major illness or congenital anomalies namely 
Cerebral palsy, developmental delay, Dandy walker syndrome, lower anorectal anomaly and 
cleft lip.
In HIV exposed babies group 2 (4%) had major illness or congenital anomalies when 
compared  to  5  (10%)  of  the  HIV  unexposed  babies  who  had  major  illness  or  congenital 
anomalies.
HIV exposed babies were found to be 1.1 times more at risk for major illness or congenital 
anomalies [RR:1.1 with 95% CI (0.3 – 4) and p = 0.82] when compared to HIV unexposed 
babies but the difference was not statistically significant.
 Comparision of minor illnesses among HIV exposed and unexposed babies
Table: 7 Comparision of infections among HIV exposed and un exposed babies
ILLNESS GROUP
SAMPLE
SIZE
MEAN 
EPISODES
STANDARD 
DEVIATION
(S.D)
STUDENT 
INDEPENDANT 
t-TEST
URI Exposed 50 3.58 2.977
Unexposed 100 4.06 2.356
t=1.08 P=0.28
not significant
AWD Exposed 50 2.28 2.214
Unexposed 100 1.17 1.364
t=3.78 P=0.001
significant
ASOM Exposed 50 .62 .855
Unexposed 100 .11 .373
t=5.08 P=0.001
significant
CSOM Exposed 50 .42 .499
Unexposed 100 .07 .256
t=5.68 P=0.001
significant
LRI Exposed 50 .40 .700
Unexposed 100 .31 .598
t=0.82 P=0.42
not significant
where URI is upper respiratory tract infection, AWD is acute watery diarrhea, ASOM is 
acute suppurative otitis media, CSOM is chronic suppurative otitis media and LRI is lower 
respiratory tract infection.
The mean number of episodes of upper respiratory tract infections was 3.5 (S.D = 2.977) 
for HIV exposed babies when compared to 4.06 (S.D = 2.356) for HIV unexposed babies. 
There was no statistically significant difference in the risk of upper respiratory tract infections 
in HIV exposed when compared to HIV unexposed babies (p = 0.28)
The mean number of episodes of acute watery diarrhoea was 2.28 (S.D = 2.214) for HIV 
exposed babies when compared to 1.17 (S.D = 1.364) for HIV unexposed babies. HIV exposed 
babies were 2.29 times at increased risk for developing acute watery diarrhoea when compared 
to HIV unexposed babies [RR: 2.29 with 95% CI = (1.15- 5.98) and p = 0.05].
The mean number of episodes of acute suppurative otitis media was 0.62 (S.D = 0.855) 
for HIV exposed babies when compared to 0.11 (S.D = 0.373) for HIV unexposed babies. HIV 
exposed babies were 7.78 times at increased risk of developing acute suppurative otitis media 
when compared to HIV unexposed babies [RR: 7.78 with 95% CI = (2.84-21.2) and p = 0.001].
The mean number of  episodes  of  chronic  suppurative  otitis  media  was 0.42 (S.D = 
0.499)  for  HIV  exposed  babies  when  compared  to  0.07  
(S.D = 0.256) for HIV unexposed babies. HIV exposed babies were 9.18 times at increased risk 
of developing chronic suppurative otitis media when compared to HIV unexposed babies 
[RR: 9.18 with 95% CI = (3.13-26.8) and p = 0.001].
The mean number of episodes of lower respiratory tract infections was 0.40 (S.D = 0.7) 
for HIV exposed babies when compared to 0.31 (S.D = 0.598) for HIV unexposed babies. 
There was no statistically significant difference in the risk of lower respiratory tract infections 
in HIV exposed when compared to HIV unexposed babies (p = 0.82)  
Table: 8 Comparision of other illnesses among HIV exposed and un exposed babies
ANEMIA
n(%)
IMPETIGO
n(%)
WORM 
INFEST.
n(%)
GEN. LN
n(%)
HIV EXPOSED 8 (16%) 4 (8%) 3 (6%) 2 (4%)
HIV UNEXPOSED 15 (15%) 7 (7%) 0 (0%) 0 (0%)
Among the HIV exposed babies, 8(16%) had anemia when compared to 15(15%) of the HIV 
unexposed  babies.  HIV  exposed  babies  were  found  to  be  at  equal  risk  for  anemia  when 
compared to HIV unexposed babies 
[RR:1 with 95% CI (0.5 – 2) and p = 0.83]
In HIV exposed babies group 4(8%) had impetigo when compared to 7(7%) of the HIV 
unexposed babies. HIV exposed babies were found to be 1.1 times more at risk for impetigo 
[RR:1.1 with 95% CI (0.3 – 4) and p = 0.82] when compared to HIV unexposed babies but the 
difference was not statistically significant
Of the 50 HIV exposed babies 3(6%) had worm infestation when compared to nil among 
the  HIV unexposed babies.  HIV exposed babies  were  found to  be  more at  risk for  worm 
infestations  (p = 0.01)  when compared to  HIV unexposed babies.  Of the  50 HIV exposed 
babies  2(4%)  had  generalized  lymphadenopathy  when  compared  to  nil  among  the  HIV 
unexposed babies. HIV exposed babies were found to be more at risk for worm infestations  
(p = 0.04) when compared to HIV unexposed babies [Table 8].
 Comparision of mortality rate among HIV exposed and un exposed babies 
Mortality rate at 18 months among HIV exposed babies – 2 (4%)
Mortality rate at 18 months among HIV non exposed babies – 1 (1%)
HIV exposed babies  were  4 times  at  risk  for  death  within  18  months  of  age when 
compared to HIV unexposed babies but it did not achieve statistical significance (p = 0.53).
Out of the 2 babies born to HIV positive mother who died within the first year:
1) The first baby was a female baby born to a primi mother by labor naturalis. Mother was 
a previously detected HIV patient belonging to AIDS clinical stage 4 with CD4 count 
101 cells on highly active Antiretroviral therapy. She had anemia during pregnancy and 
was treated with oral iron and folic acid tablets. The birth weight of the baby was 2.7 
kgs and was started on Zidovudine prophylaxis for 6 weeks postnatally Mother breastfed 
the baby. The neonatal period was uneventful.  At 40 days of life the baby  presented 
with loose stools lasting a week on examination the baby  had severe visible wasting, 
oral  thrush,  severe  dehydration,  generalized  lymphadenopathy,  and 
hepatospelenomegaly.  The  baby  was  treated  aggressively  with  oxygen,  intravenous 
fluids,  intravenous antibiotics  and other  supportive  measures.  Investigations revealed 
bronchopneumonia  in  chest  radiograph,  blood  counts  showed  anemia  and 
thrombocytopenia, metabolic parameters were normal, CSF analysis was within normal 
limits and blood culture was awaited. HIV PCR was positive, CD4 count was 50 cells. 
The baby died after 26 hours of admission due to decompensated septic shock.
2) The second  was a preterm ( gestational age: 36 –38 week) IUGR baby delivered to a 
primi mother by cesarian section who was a clinical stage 3 AIDS patient with antenatal 
CD4 count of 200 cells. She was on highly active antiretroviral therapy. The baby was 
given Zidovudine prophylaxis for 6 weeks postnatally. The baby was admitted in the 
medical  new born ward  for  10 days  and discharged on breastfeeds  as  per  mothers 
option. The baby was given mixed feeding upto 6 weeks of life after which started on 
cotrimoxazole prophylaxis and stopped breast feeds as per advice. The baby was under 
nourished, with several episodes of diarrhoea which was managed accordingly. At five 
months HIV PCR was negative. At 6 months of age the baby presentated with fever, 
altered level of sensorium and seizures. Baby was admitted and started on anti epileptic 
medication, intravenous fluids, intravenous antibiotics and other supportive measures. 
Investigations revealed severe anemia, thrombocytosis,  blood biochemical parameters 
were  within  normal  limits.  CSF  analysis  revealed  polymorphonuclear  leucocytosis, 
elevated protein, and pneumococcus in gram stain. Blood culture was negative. Baby 
died after  49 hours of admission. 
Lab diagnosis of HIV infection
• HIV PCR results of HIV exposed babies
Total no of HIV exposed babies screened by HIV-PCR – 50
No of HIV exposed babies with HIV PCR negative – 49
No of HIV exposed babies with HIV PCR positive – 1
• HIV- ELISA test results done at 18 months of age
Total no of HIV exposed babies screened - 48
No of HIV exposed babies with HIV- ELISA negative – 48
No of HIV exposed babies with HIV ELISA positive – 0
Mother to child HIV transmission rate = 1 (2%) 
DISCUSSION
India has a population of one billion, around half of whom are adults in the sexually 
active age group. According  to WHO/UNAIDS, there are estimated  24,00,000 people living 
with HIV/AIDS at  the  end of  2007 of  whom one lakh are children [7].  The average HIV 
prevalence among women attending antenatal clinics in India is 0.88% [7]. This emphasizes the 
burden of HIV in our country . Around 25% to 50% of such mothers transmit the disease to 
their  children  [6].  Number  of  pregnant  women  living  with  HIV/AIDS  who  received 
antiretrovirals for preventing parent to child transmission in 2007 is 8816 (which is 14% of 
estimated  pregnant  women  living  with  HIV/AIDS)  [7]  depicting  the  need  for  more 
concentration in that area.There are very few studies especially from south India telling about 
impact of HIV on birth and early years of the child born to HIVpositive mothers. So our study 
on the outcome of children born to HIV positive mothers in terms of mortality and morbidity is 
important in our setup which caters to such mothers.
Our study shows that the parent to child transmission (PTCT) of HIV was only 2%. 
Whereas the rates were very high as quoted by Rosemary, et al from Rwanda, Africa during 
1988 – 1994 of 24.7% [8], Adhikari, et al from Durban, South Africa of 28% [14], Blanche, et 
al from France of 27% [10]. These studies were done before the use of effective antiretrovirals 
for prevention of parent to child transmission of HIV. Similar studies in India by Bal Runa et al 
from West Bengal revealed a PTCT rate of 18.1% [12] but in that study the final number of 
children tested for HIV at 18 months of age was only 23% of the initial number of babies. A 
multicentric study HIVNET 012 revealed a PTCT rate of 13.1% [21],  this low rate of PTCT in 
our study can be explained by the fact that the HIV seropositive mothers were evaluated for 
AIDS and started on combination anti  retroviral therapy as per WHO guidelines.  Only the 
asymptomatic  mothers  were  given  single  dose  of  nevirapine  for  prevention  of  perinatal 
transmission of HIV. 
In our study, there was no significant difference in birth weight among HIV exposed and 
unexposed infants. Similar results were quoted by Gail, et al from Bronx & Brooklyn in U.S.A 
[11] and Blanche, et al. from France [10] But Ryder et al from Zaire, Africa has found that 
children born to HIV positive mothers had lower birth weights [9]. This difference would bee 
explained as  follows,  even though the  percentage of  mothers  with AIDS were  comparable 
between our study and that of Ryder, et al (16% vs 17.8% ) [9], in our study such mothers were 
started on combination retroviral therapy which influenced the results. 
Maternal anemia and wasting were more in HIV positive than in negative, but there was 
no difference in other obstetrical complications between the two groups. Similar results were 
obtained by Gail, et al from Bronx & Brooklyn in U.S.A [11]. 
In our study the rate of cesarean delivery was 48% among HIV positive which was 
similar to that of HIV negative mothers (42%). Whereas Rashid, et al from Mumbai, India 
[13]and Bal Runa, et al from West Bengal [12] has reported 18% and 4.7% respectively. These 
results need further large studies before being commented on.
Neonatal period was similar in both HIV exposed and unexposed babies in our study 
which is similar to the observations of Gail, et al from Bronx & Brooklyn in U.S.A [11. But 
Ryder, et al from Zaire, Africa [9] reports a higher rate of neonatal deaths among HIV exposed 
babies.  This  difference would be  explained on the  basis  of  differences  in  socio economic, 
cultural and availability of medical facilities in the different settings. 
In our study only 12% of mothers opted for replacement feeds whereas Rashid, et al 
from Mumbai, India [13] in his study had 88% of the mothers preferring replacement feeds. 
This may be due to the cultural beliefs of the people.
Our babies on follow up had similar patterns of growth and development irrespective of 
their maternal HIV status. This detail was not given by other studies. 
In our study HIV exposed babies had an increased frequency of acute watery diarrhea 
and suppurative otitis media. This is contradictory to Rosemary, et al from Rwanda, Africa [8] 
who observed similar morbidity pattern among HIV exposed and unexposed babies in the early 
years. The increased frequency of acute watery diarrhea and suppurative otitis media may be 
due to feeding technique ( gavage feeding vs breast feeding), which needs larger studies to 
arrive at a conclusion. 
The mortality rate was not significantly more among the HIV exposed in our study, 
whereas Ryder et al from Zaire, Africa [9] has quoted a 6 times increased risk of death among 
HIV exposed babies when compared to HIV unexposed babies. This observation could be due 
to difference in the perinatal transmission rate of HIV and rate of symptomatic AIDS among 
the two studies.
SUMMARY
Thus our study on the outcome of HIV exposed babies has the following findings:
No. of HIV exposed babies studied = 50
No. of HIV unexposed babies studied = 100
No. of HIV exposed babies infected with HIV = 1 (2%)
Birth characteristics and neonatal morbidity was similar in both the HIV exposed and 
unexposed babies.
Growth and Development was similar in HIV exposed and unexposed babies.
Acute watery diarrhea and otitis media were more common in the HIV exposed when 
compared to HIV unexposed babies.
Worm infestation and generalized lymphadenopathy were more common in the HIV 
exposed when compared to HIV unexposed babies.
There was no difference in the mortality among HIV exposed and unexposed babies.
The parent to child HIV transmission rate was 2% in our study.
CONCLUSION
Thus our study has found that HIV exposed babies are not at additional risk for neonatal 
adverse  outcomes  when  compared  to  unexposed  babies.  Growth,  development  and  major 
congenital anomalies are not influenced by HIV exposure.  Acute watery diarrhea and otitis 
media are more common among HIV exposed when compared to HIV unexposed babies. 
But these findings have to be confirmed by larger prospective studies.
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ANNEXURE
AT BIRTH  
Mother's Name: Education : Employment :
Serial No. : HIV status : Illness :
Breast feeding option : Treatment details :
Father's Name and Address: Education : Employment :
HIV status : Illness :
Treatment  details :
Baby :
Serial No. : Gestational Age : Birth Weight :
Length : Head Circumference : Apgar :
General Examination :
Congenital Anomalies :
Treatment :
FOLLOW UP
Baby Name :
Serial No :
Specific Complaints :
Weight : Head Circumference : Length: 
General Examination :
Systems Examination :
Feeding : Immunisation :
Nutrition : Development  :
Cotrimoxazole prophylaxis :
Other Treatment :
